Global Genital Warts Market Analysis 2024 – Estimated Market Size And Key Drivers

The Genital Warts Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Genital Warts Market:
https://www.thebusinessresearchcompany.com/report/genital-warts-global-market-report

According to The Business Research Company’s Genital Warts Global Market Report 2024, The genital warts market size has grown strongly in recent years. It will grow from $1.87 billion in 2023 to $1.97 billion in 2024 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to the focus on patient-centered care, growing emphasis on early detection and treatment, increasing availability of therapies developed for self-target applications, and the increase in clinical trials and recurrence of genital warts.

The genital warts market size is expected to see strong growth in the next few years. It will grow to $2.44 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to the adoption of telemedicine and digital health platforms for remote consultation and treatment monitoring, growing demand for effective and affordable treatments for STIs, the emerging popularity of loop electrosurgical excision procedures, the escalating demand for interferon alfa-n3 injection and increasing availability of therapies. Major trends in the forecast period include advancements in diagnostic technologies, a shift towards combination therapies, expansion of telehealth and online consultations, emergence of novel therapeutic targets, and expansion in emerging markets.

The increasing prevalence of sexually transmitted infections (STIs) propels the growth of the genital warts market going forward. Sexually transmitted infections (STIs) are infections that are primarily transmitted through sexual contact, including vaginal, anal, and oral sex, and are caused by bacteria, viruses, or parasites. The prevalence of sexually transmitted infections is growing due to increased sexual activity, inadequate use of protection, and limited access to education and healthcare services. Genital warts are a common sexually transmitted infection (STI) caused by specific strains of the human papillomavirus (HPV). They spread through direct skin-to-skin contact during sexual activity. For instance, in October 2023, according to the Joint United Nations Programme on HIV/AIDS, a Switzerland-based, comprehensive global program to prevent HIV infection, in 2021, around 38.7 million people were infected with HIV, which increased to 39.0 million people in 2022, with 1.3 million newly infected people in the year 2022. Therefore, the increasing prevalence of sexually transmitted infections (STIs) is driving the growth of the genital warts market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=18374&type=smp

The genital warts market covered in this report is segmented –

1) By Drug Type: Imiquimod, Podophyllin, Podofilox, Trichloroacetic Acid
2) By Treatment: Chemical Treatment, Ablative Treatment, Preventive Treatment, Other Treatments
3) By Gender: Female, Male
4) By End Users: Hospitals, Clinics, Home Care Settings

Major companies operating in the genital warts market are developing novel treatment options, such as novel dermatology drugs, to address the challenges faced by patients with genital warts. Dermatology drugs refer to newly developed pharmaceuticals or therapeutic agents specifically designed to treat various dermatologic conditions, such as genital warts. For instance, in March 2023, Verrica Pharmaceuticals Inc., a US-based dermatology pharmaceutical company, received New Chemical Entity (NCE) status for its drug candidate YCANTH. YCANTH is being developed to treat genital warts and has completed phase 2 trials. With FDA NCE status, the company now has at least five years of protection from generic competition.

The genital warts market report table of contents includes:

1. Executive Summary
2. Genital Warts Market Characteristics
3. Genital Warts Market Trends And Strategies
4. Genital Warts Market – Macro Economic Scenario
5. Global Genital Warts Market Size and Growth
.
.
.
32. Global Genital Warts Market Competitive Benchmarking
33. Global Genital Warts Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Genital Warts Market
35. Genital Warts Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model